IDT’s strong quarter delivers growth
Posted: 13 July 2023 Pharmaceutical manufacturer IDT Australia is seeing a surge in sales as demand for medical cannabis products rises and companies seek out more capable contract development and manufacturing organisations (CDMO). The Melbourne company told investors…
Monash-Alfred-Baker join forces to improve heart health
Posted: 13 July 2023 A new cardiovascular research centre is bringing together Monash University, the Baker Heart and Diabetes Institute and Alfred Health to boost opportunities for academic-clinician partnered research and offer new pathways for emerging research talent in the Alfred Research Alliance Precinct.…
Monash University buys CSIRO’s Parkville property; Australia’s biomedical research sector set to expand
Posted: 13 July 2023 Monash University has acquired a prime Parkville property that will become a key addition to its Parkville campus – home to Monash’s world-leading Faculty of Pharmacy and Pharmaceutical Sciences – and significantly advance Australia’s…
Professor Mark Dawson receives prestigious grant
Posted: 13 July 2023 Professor Mark Dawson, Head of Cancer Epigenetics Laboratory at Peter Mac has been awarded a Translational Research Program (TRP) grant worth USD $750,000 to further his research to help overcome acquired resistance to anti-cancer…
Published trial results find Atmo Gas Capsule can detect changes in regional colonic fermentation in IBS patients
Posted: 11 July 2023 Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced results from a clinical study have found that its gas-sensing capsule can…
Dimerix Receives Approval for Paediatric Investigation Plan from the EMA
Posted: 10 July 2023 Dimerix Limited (ASX: DXB), a biopharmaceutical company with Phase 3 clinical studies in inflammatory diseases, today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) accepted its Paediatric Investigation Plan (PIP)…
New AD-214 Data Links Phase I Results with Efficacy, De-risks Clinical Dosing Schedule
Posted: 7 July 2023 ASX Announcement Key points: New data favourably links AD-214 preclinical animal studies and Phase I human clinical trial results to provide important dose frequency insights AD-214 is designed to treat fibrotic diseases such as…
“Jumar Bioincubator” calls for next-gen biotechs, appoints new GM
Posted: 4 July 2023 Australia’s newest biotech incubator is calling for innovative early-stage Australian biotechs to take up residency in its much-awaited Melbourne-based facility. The “Jumar Bioincubator” will be supported by cash and in-kind contributions of approximately $45 million over…
Dimerix Confirms Phase 3 FSGS Kidney Disease Stud Design Appropriate For China
Posted: 4 July 2023 Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical study in inflammatory disease, today confirmed that the Chinese regulatory agency, National Medical Products Administration (NMPA) has provided a written response on…
Neuren completes enrolment in Phelan-McDermid syndrome Phase 2 trial
Posted: 4 July 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that enrolment of subjects into its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome has now been completed. Topline results from the trial are expected to be…
Important Phase I Extension Clinical Study of AD-214 Approved
Posted: 30 June 2023 AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform, is pleased to announce that it has received Human Research Ethics Committee (HREC) approval to commence a…
Neuren opens first site in US for Prader-Willi syndrome Phase 2 trial
Posted: 28 June 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that the first site in the United States for its Phase 2 clinical trial of NNZ-2591 in Prader-Willi syndrome is now open. Neuren CEO Jon Pilcher commented “The…
